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Abstract
Objective: Nonalcoholic fatty liver disease (NAFLD) affects 9.6% of children and
may put these children at elevated risk of high blood pressure and subsequent
cardiovascular morbidity and mortality. Therefore, we sought to determine the
prevalence of and risk factors for high blood pressure in children with NAFLD.
Methods: Cohort study performed by the NIDDK NASH Clinical Research Network.
There were 484 children with NAFLD ages 2 to 17 at enrollment; 382 children were
assessed both at enrollment and 48 weeks afterwards. The main outcomes were
high blood pressure at baseline and persistent high blood pressure at both baseline
and 48 weeks.
Results: Prevalence of high blood pressure at baseline was 35.8% and prevalence
of persistent high blood pressure was 21.4%. Children with high blood pressure
were significantly more likely to have worse steatosis than children without high
blood pressure (mild 19.8% vs. 34.2%, moderate 35.0% vs. 30.7%, severe 45.2%
vs. 35.1%; P50.003). Higher body mass index, low-density lipoprotein, and uric
acid were independent risk factors for high blood pressure (Odds Ratios: 1.10 per
kg/m2, 1.09 per 10 mg/dL, 1.25 per mg/dL, respectively). Compared to boys, girls
with NAFLD were significantly more likely to have persistent high blood pressure
(28.4% vs.18.9%; P50.05).
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"
Conclusions: In conclusion, NAFLD is a common clinical problem that places
children at substantial risk for high blood pressure, which may often go
undiagnosed. Thus blood pressure evaluation, control, and monitoring should be an
integral component of the clinical management of children with NAFLD.
Introduction
High blood pressure and nonalcoholic fatty liver disease (NAFLD) are two
emerging clinical problems in children closely related to the epidemic of
childhood obesity. NAFLD is now the most common cause of chronic liver disease
in children in the United States with an estimated prevalence of 9.6%. [1] The
prevalence of high blood pressure is estimated to be between 2 and 5% among
children in the United States. [2], [3] High blood pressure in childhood is likely to
persist into adulthood [4], [5] and is a risk factor in adulthood for atherosclerosis
and coronary heart disease. [6]
NAFLD itself has been linked to cardiovascular disease in both children and
adults. [7–9] In adults with NAFLD, cardiovascular disease is the leading cause of
death. [10], [11] In children with NAFLD, studies have reported high blood
pressure as part of the metabolic syndrome; however, blood pressure has not been
evaluated as the focal point of any of these studies. [9], [12], [13] Thus, many
questions remain about the prevalence of high blood pressure and its associated
risk factors in children with NAFLD. Moreover, there have been no longitudinal
studies of blood pressure among children with NAFLD. Therefore we performed a
multi-center, longitudinal cohort study with the following study aims: 1) to
determine the prevalence of high blood pressure in children with NAFLD in
relation to demographic and key clinical risk factors, and 2) to determine the rate
and risk factors of persistent (over 48 weeks) high blood pressure in children with
NAFLD.
Methods
Study population
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NASH Clinical Research Network (NASH CRN) enrolled children with NAFLD in
longitudinal cohort studies (Database and Database 2; NCT01061684) and a
randomized controlled trial (TONIC; NCT00063635). These studies have been
described [14], [15] and were performed at 13 pediatric clinical centers across the
United States (see appendix for list). NAFLD Database began enrollment in
September 2004, TONIC in August 2005 and Database 2 in October 2009.
Children completed annual visits with comprehensive anthropometric and
laboratory measurements described below. For this analysis, we included children
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who were ,18 years of age at baseline with NAFLD. A diagnosis of NAFLD was
based on liver histology with >5% of hepatocytes containing macrovesicular fat
and exclusion of other causes of chronic liver disease by clinical history, laboratory
studies, and histology. [16] For the baseline analysis, we excluded children with
underlying renal disease, those without a histologic diagnosis of NAFLD, or
missing blood pressure at baseline. For the longitudinal analysis, we excluded
those without follow-up data at 48 weeks.
Ethics Statement
All studies were approved by the Institutional Review Boards at each participating
center. Written informed consent was obtained from parents/guardians and
written assent was obtained from children.
Liver Histology
All liver biopsy specimens were stained with hematoxylin-eosin and Masson’s
trichrome stains, and reviewed and scored centrally by the Pathology Committee
according to the published NASH Clinical Research Network scoring system. [17]
The Pathology Committee was blinded to any clinical or demographic
information. Steatosis was graded according to the percentage of hepatocytes that
contained fat droplets as follows: grade 0, none: ,5%; grade 1, mild: 5 to 33%;
grade 2, moderate: 34 to 66%; and grade 3, severe:. 66%. Fibrosis was staged as
follows: a) stage 1a – mild zone 3 perisinusoidal fibrosis requiring trichrome stain;
b) stage 1b – moderate zone 3 perisinusoidal fibrosis not requiring trichrome
stain; c) stage 1c – portal/periportal fibrosis only; c) stage 2 –zone 3 perisinusoidal
fibrosis and periportal fibrosis; d) stage 3 – bridging fibrosis; and e) stage 4 –
cirrhosis. Liver biopsies were diagnosed as steatohepatitis, borderline steatohe-
patitis or NAFLD but not steatohepatitis, based on the aggregate presence and
degree of the individual histologic features of fatty liver disease. Although no
single histologic feature is considered diagnostic of NASH, a typical set of
minimum criteria would include macrovesicular steatosis (more than 5%),
lobular inflammation and hepatocyte injury as manifest by ballooning
degeneration. Borderline cases demonstrated a lesser degree of one or more
findings. Cases determined to be NAFLD but not steatohepatitis NASH show
steatosis with no or minimal lobular inflammation. The assignment of a diagnosis
of steatohepatitis, borderline steatohepatitis or NAFLD but not steatohepatitis was
made as a consensus agreement of the NASH CRN pathology group at the time of
central review of cases.
Measures
Physical measurements included height, weight, waist circumference, systolic
blood pressure, and diastolic blood pressure. Blood pressure was measured and
percentiles were computed as instructed in The Fourth Report on the Diagnosis,
Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.
High Blood Pressure in Pediatric NAFLD
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[18] After 5 minutes of seated rest, blood pressure was measured twice from the
right arm of the seated child with an automated sphygmomanometer with
1 minute of rest between measurements. The average of the 2 measures was
recorded. Cuff sizes were selected so that the cuff bladder encircled at least 80% of
the mid-upper arm per standard protocol. Participants fasted overnight for
12 hours before phlebotomy. Fasting laboratory assays included glucose, insulin,
total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, triglycerides, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), gamma glutamyltransferase (GGT), and uric
acid. Body mass index (BMI) was calculated as weight (kg) divided by height (m)
squared.
Case definitions
The definitions for blood pressure in children are based upon the normative
distribution of blood pressure in healthy children. [18] High blood pressure is
defined as average systolic or diastolic blood pressure that is >95th percentile for
age, sex, and height. Hypertension is defined as high blood pressure on at least
three separate occasions. For this analysis we defined High blood pressure as
systolic or diastolic blood pressure >95th percentile for age, sex and height, or the
use of antihypertensive medication for a clinical diagnosis of hypertension.
Persistent high blood pressure was defined as having high blood pressure at both
baseline and at 48 weeks. Clinical hypertension was determined by parental or
patient report that a child had a clinical diagnosis of hypertension assigned by
their treating physician.
Data Analysis
Descriptive statistics (mean, standard deviation, frequency, and percentages) were
used to compare patients with and without elevated blood pressure; P values were
determined either from Chi-square tests for categorical variables or from non-
parametric two-sample Wilcoxon rank sum tests for continuous variables. Risk
factors for high blood pressure were identified using multiple logistic regression
models with the presence of high blood pressure as the binary outcome and a
candidate set of risk factors: gender, age, race/ethnicity (non-Hispanic white,
Hispanic, and non-Hispanic non-white), BMI, GGT, LDL, glucose, insulin, and
uric acid. Goodness of fit of the logistic model was assessed using a Hosmer-
Lemeshow chi-square test with P.0.05 indicating adequate fit. Parallel analyses
were done for risk factors for persistently high blood pressure. Characteristics of
those children with and without 48 week follow-up were compared using a logistic
regression model of the odds of missing-ness in relation to the risk factors; a Wald
test was performed to determine whether set of characteristics differed in those
children who were not evaluated at a 48 week follow-up assessment. All analyses
assumed nominal, two-sided P values as statistically significant if P#0.05.
Analyses were performed using SAS version 9.3 (SAS Institute) and Stata version
High Blood Pressure in Pediatric NAFLD
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13.1 (StataCorp). Sensitivity analysis of variation in risk factors by gender showed
no evidence of effect modification (interaction P range from 0.12 to 0.81).
Additionally, the set of risk factors was not related to the odds of missing the 48
week follow-up visit (P50.41).
Results
Study population
There were 494 children enrolled in the NASH CRN that met all criteria and were
included in the baseline analysis. A study flow chart is shown in Figure 1. The
demographic and clinical parameters are shown in Table 1. The mean age of the
participants at baseline was 13.1 years. The mean BMI of participants at baseline
was 32.7 kg/m2. The distribution of disease severity was: NAFLD but not NASH
27.5% (136/494), borderline NASH 44.7% (221/494) and definite NASH 27.7%
(137/494). The majority of participants (358/494) were boys. There was no
significant difference between boys and girls with respect to age or race/ethnicity.
Figure 1. Flowchart shows the application of study inclusion and exclusion criteria.
doi:10.1371/journal.pone.0112569.g001
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Table 1. High Blood Pressure in Children with NAFLD—Baseline Characteristics.
High Blood Pressurea
Characteristics No Yes Total P Valueb
N (%) or mean ¡SD N5317 N5177 N5494
Blood pressure
Systolic blood pressure percentile 64.1¡25.0 95.8¡24.0 75.5¡26.0 ,0.0001
Diastolic blood pressure percentile 53.9¡23.6 73.8¡21.9 61.0¡24.9 ,0.0001
Demographics
Male 234 (73.8%) 124 (70.1%) 358 (72.5%) 0.37
Age (years)c 13.1¡2.7 12.9¡2.8 13.1¡2.7 0.35
,8 years 11 (3.5%) 6 (3.4%) 17 (3.4%) 0.33
8–12 years 141 (44.5%) 91 (51.4%) 232 (47.0%)
13–17 years 165 (52.1%) 80 (45.2%) 245 (49.6%)
Race/ethnicity 0.05
Non-Hispanic white 85 (26.8%) 63 (35.6%) 148 (30.0%)
Hispanic 216 (68.4%) 101 (57.1%) 317 (64.2%)
Other 16 (5.1%) 13 (7.3%) 29 (5.9%)
Anthropomorphic
BMI z-score 2.2¡0.4 2.4¡0.4 2.3¡0.4 ,0.0001
BMI (kg/m2) 31.6¡6.2 34.6¡6.5 32.7¡6.5 ,0.0001
Liver enzymes
ALT (U/L) 105.9¡84.3 107.1¡88.8 106.3¡85.8 0.83
AST (U/L) 63.2¡48.5 64.6¡45.3 63.7¡47.3 0.41
GGT (U/L) 42.4¡29.9 48.6¡34.5 44.6¡31.7 0.004
Serum chemistries
HDL (mg/dL) 38.5¡8.5 38.2¡10.1 38.4¡9.1 0.17
LDL (mg/dL) 100.2¡29.9 106.4¡28.7 102.4¡29.6 0.04
Serum glucose (mg/dL) 87.7¡18.1 89.3¡15.0 88.3¡17.1 0.05
Serum insulin (mU/mL) 31.7¡38.5 37.4¡28.5 33.7¡35.3 0.001
HOMA-IRd 7.0¡9.3 8.3¡6.7 7.5¡8.5 0.001
Uric acid (mg/dL) 5.9¡1.4 6.3¡1.4 6.0¡1.4 0.03
Liver Histology
Steatosis grade 0.003
,33% 108 (34.2%) 35 (19.8%) 143 (29.0%)
34–66% 97 (30.7%) 62 (35.0%) 159 (32.3%)
.66% 111 (35.1%) 80 (45.2%) 191 (38.7%)
Lobular inflammation 0.94
,2 under 20x 173 (54.8%) 95 (53.7%) 268 (54.4%)
2–4 under 20x 122 (38.6%) 71 (40.1%) 193 (39.2%)
.4 under 20x 21 (6.7%) 11 (6.2%) 32 (6.5%)
Ballooning 0.02
None 174 (55.1%) 96 (54.2%) 270 (54.8%)
Few 81 (25.6%) 61 (34.5%) 142 (28.8%)
Many 61 (19.3%) 20 (11.3%) 81 (16.4%)
Fibrosis stage 0.47
None 102 (32.4%) 44 (25.0%) 146 (29.7%)
High Blood Pressure in Pediatric NAFLD
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Boys had a significantly higher BMI Z-score than girls (2.4¡0.4 vs 2.2¡0.4;
P,0.001) but no difference in BMI (32.9¡6.3 vs 32.6¡7.0 kg/m2; P50.33).
High Blood Pressure at Baseline
The estimated prevalence of high blood pressure at baseline was 35.8% (95% CI
31.7–40.2). As shown in Table 1, children with and without high blood pressure
did not differ significantly by age, sex or race. Children with high blood pressure
had a significantly higher mean BMI than children without high blood pressure
(34.6 vs. 31.6 kg/m2; P,0.0001). Children with high blood pressure also had
significantly higher GGT, LDL-cholesterol, serum fasting insulin, and uric acid
values. In addition, children with high blood pressure had significantly more
severe steatosis (mild: 19.8%, moderate: 35.0%, severe: 45.2%) than children
without high blood pressure (mild: 34.2%, moderate: 30.7%, severe: 35.1%,
P50.003). As shown in Table 2, each one unit increase in BMI was associated
with 10% greater odds of having high blood pressure (95%CI: 6%–14%). There
was a significant linear relationship between LDL-cholesterol and odds of high
blood pressure (OR [95%CI]: 1.09 per 10 mg/dL [1.02, 1.17]). In addition, for
every 1 mg/dL of uric acid there was a 25% increase in the odds of having high
blood pressure (95%CI: 6%–48%).
Persistent High Blood Pressure
The estimated prevalence of persistent high blood pressure was 21.4% (95%CI
17.6–25.9). Girls with NAFLD were significantly more likely to have persistent
Table 1. Cont.
High Blood Pressurea
Characteristics No Yes Total P Valueb
N (%) or mean ¡SD N5317 N5177 N5494
Zone 3, perisinusoidal or portral/periportal only 121 (38.4%) 73 (41.5%) 194 (39.5%)
Zone 3, periportal 49 (15.6%) 30 (17.1%) 79 (16.1%)
Bridging 38 (12.1%) 27 (15.3%) 65 (13.2%)
Cirrhosis 5 (1.6%) 2 (1.1%) 7 (1.4%)
Diagnosis 0.42
NAFLD, not NASH 93 (29.3%) 43 (24.3%) 136 (27.5%)
Borderline NASH 136 (42.9%) 85 (48.0%) 221 (44.7%)
Definite NASH 88 (27.8%) 49 (27.7%) 137 (27.7%)
Abbreviations: BMI5body mass index, ALT5alanine aminotransferase, AST5 aspartate aminotransferase, GGT5gamma-glutamyl transpeptidase,
HDL5high-density lipoprotein, LDL5low-density lipoprotein, HOMA-IR5homeostasis model of assessment - insulin resistance
aWe defined high blood pressure as systolic or diastolic blood pressure§95th percentile for age, sex and height or the use of antihypertensive medication.
Blood pressure percentiles were computed as instructed in The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in
Children and Adolescents.
bP values determined from chi square tests for categorical variables and from two-sample Wilcoxon rank sum tests for continuous variables due to the
presence of non-normality.
cAge range from 2–17 years.
dHOMA-IR units are (mg/dL6IU/mL/405).
doi:10.1371/journal.pone.0112569.t001
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high blood pressure than boys with NAFLD (28.4% [20.5%–38.0%] vs.18.9%
[14.7%–24.0%]). As shown in Table 3, children with persistent high blood
pressure were more likely to be non-Hispanic white (36.6% vs. 27.7%). Similar to
the differences seen at baseline, children with persistent high blood pressure had
significantly higher values of GGT, LDL-cholesterol, insulin, and uric acid than
children without persistent high blood pressure. There was no significant
difference in the severity of any histologic feature between children with and
without persistent high blood pressure. In multivariate analysis (Table 4), boys
with NAFLD had 45% lower odds of having persistent high blood pressure than
girls with NAFLD (95%CI: 3–69%). BMI, LDL-cholesterol, and uric acid were all
significantly positively associated with the odds of having persistent high blood
pressure (OR[95%CI]: 1.10[1.05, 1.15], 1.12[1.03, 1.23], 1.32[1.06, 1.64],
respectively). Sensitivity analysis of variation in risk factors by gender showed no
evidence of effect modification (interaction P range from 0.12 to 0.81).
Table 2. Clinical, Demographic, and Biochemical Risk Factors for High Blood Pressure at Baseline.
Odds Ratios (OR) for High Blood Pressurea
Single variable logistic Adjusted, Multivariable Logistic
Risk Factors OR (95%CI) P Valueb OR (95% CI) P Valueb
Demographics
Male vs Female 0.83 (0.55, 1.25) 0.37 0.71 (0.45, 1.12) 0.14
Age/year 0.98 (0.91, 1.04) 0.47 0.82 (0.75, 0.90) ,0.001
Race/ethnicity 0.05 0.36
Non-Hispanic white 1.0 (Reference) 1.0 (Reference)
Hispanic 0.63 (0.42, 0.94) 0.03 0.84 (0.53, 1.33) 0.46
Other 1.10 (0.49, 2.44) 0.82 1.51 (0.62, 3.63) 0.36
Anthropomorphic
BMI/(kg/m2) 1.08 (1.04, 1.11) ,0.001 1.10 (1.06, 1.14) ,0.001
Liver enzymes
GGT/(10 U/L) 1.06 (1.00, 1.12) 0.04 1.03 (0.96, 1.09) 0.44
Serum chemistries
LDL/(10 mg/dL) 1.07 (1.01, 1.14) 0.03 1.10 (1.03, 1.18) 0.006
Serum glucose/(10 mg/dL) 1.06 (0.95, 1.18) 0.32 1.07 (0.96, 1.19) 0.25
Serum insulin/(10 mU/mL) 1.05 (0.99, 1.11) 0.11 1.01 (0.96, 1.07) 0.70
Uric acid/(mg/dL) 1.18 (1.03, 1.35) 0.02 1.25 (1.05, 1.49) 0.01
Liver histology
Steatosis grade.33% 2.11 (1.36, 3.26) 0.001 2.26 (1.39, 3.66) 0.001
Intercept 0.01 (0.001, 0.08) ,0.001
Hosmer-Lemeshow x2 for model fit 0.94
Abbreviations: OR5odds ratio, CI5confidence interval, BMI5body mass index, GGT5gamma-glutamyl transpeptidase, LDL5low-density lipoprotein.
aHigh blood pressure was defined as systolic or diastolic blood pressure§95th percentile for age, sex and height or the use of antihypertensive medication.
Blood pressure percentiles were computed as instructed in The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in
Children and Adolescents.
bP values and 95% CI were obtained from Wald statistics.
doi:10.1371/journal.pone.0112569.t002
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Table 3. Persistently High Blood Pressure in Children with NAFLD—Baseline Characteristics.
Persistently High Blood Pressurea
Characteristics No Yes P Valueb
N (%) or mean¡SD N5300 N582
Blood pressure
Systolic blood pressure percentile 71.0¡25.9 95.6¡12.0 ,0.0001
Diastolic blood pressure percentile 56.6¡24.2 73.8¡24.7 ,0.0001
Demographics
Male 227 (75.7%) 53 (64.6%) 0.05
Age (years)c 13.0¡2.7 13.0¡2.6 0.85
,8 years 7 (2.3%) 2 (2.5%) 0.96
8–12 years 145 (48.3%) 41 (50.0%)
13–17 years 148 (49.3%) 39 (47.6%)
Race/ethnicity 0.007
Non-Hispanic white 83 (27.7%) 30 (36.6%)
Hispanic 205 (68.3%) 43 (52.4%)
Other 12 (4.0%) 9 (11.0%)
Anthropomorphic
BMI z-score 2.3¡0.5 2.5¡0.3 ,0.0001
BMI (kg/m2) 32.1¡6.4 35.3¡6.1 ,0.0001
Liver enzymes
ALT (U/L) 106.4¡84.9 110.2¡82.4 0.77
AST (U/L) 62.8¡44.2 69.6¡53.1 0.50
GGT (U/L) 43.9¡31.8 50.7¡36.7 0.04
Serum chemistries
HDL (mg/dL) 38.4¡8.3 37.8¡11.3 0.08
LDL (mg/dL) 100.3¡29.6 108.8¡29.8 0.03
Serum glucose (mg/dL) 88.6¡18.2 90.7¡17.2 0.05
Serum insulin (mU/mL) 33.5¡39.3 39.1¡32.4 0.04
HOMA-IRd 7.4¡9.5 8.9¡7.8 0.04
Uric acid (mg/dL) 6.0¡1.4 6.4¡1.5 0.03
Liver Histology
Steatosis grade 0.45
,33% 91 (30.3%) 19 (23.2%)
34–66% 91 (30.3%) 27 (32.9%)
.66% 118 (49.3%) 36 (43.9%)
Lobular inflammation 0.19
,2 under 20x 151 (50.3%) 47 (57.3%)
2–4 under 20x 133 (44.3%) 28 (34.2%)
.4 under 20x 16 (5.3%) 7 (8.5%)
Ballooning 0.44
None 162 (54.0%) 42 (51.2%)
Few 86 (28.7%) 29 (35.4%)
Many 52 (17.3%) 11 (13.4%)
Fibrosis stage 0.58
None 101 (33.8%) 22 (27.2%)
High Blood Pressure in Pediatric NAFLD
PLOS ONE | DOI:10.1371/journal.pone.0112569 November 24, 2014 9 / 17
Additionally, the set of risk factors was not related to the odds of missing the 48
week follow-up visit (P50.41).
Clinical Hypertension
At baseline, 18% (32/177) of children with high blood pressure had a clinical
diagnosis of hypertension. There were 10 children taking antihypertensive
medication representing 5% of those with high blood pressure and 31% of those
with a clinical diagnosis of hypertension. Over the course of one year of follow-up,
there were an additional 10 children diagnosed with hypertension.
Antihypertensive medications were prescribed to 2 additional children who had a
clinical diagnosis of hypertension at baseline and to 2 of the children subsequently
diagnosed with hypertension. At week 48, 28% (23/82) of children with persistent
high blood pressure had a clinical diagnosis of hypertension and 13% were taking
antihypertensive medications.
Discussion
We studied the prevalence of high blood pressure in a longitudinal cohort study of
children with NAFLD from pediatric centers across the United States. Children
with NAFLD had a high rate of high blood pressure both at baseline and again at
48 weeks. The odds of having high blood pressure at baseline and high blood
pressure that persisted at 48 weeks were associated with BMI, LDL-cholesterol and
uric acid. Hepatic steatosis was associated with high blood pressure at baseline.
Table 3. Cont.
Persistently High Blood Pressurea
Characteristics No Yes P Valueb
N (%) or mean¡SD N5300 N582
Zone 3, perisinusoidal or portral/periportal only 114 (38.1%) 30 (37.0%)
Zone 3, periportal 46 (15.4%) 16 (19.8%)
Bridging 35 (11.7%) 11 (13.6%)
Cirrhosis 3 (1.0%) 2 (2.5%)
Diagnosis 0.83
NAFLD, not NASH 87 (29.0%) 22 (26.8%)
Borderline NASH 135 (45.0%) 36 (43.9%)
Definite NASH 78 (26.0%) 24 (29.3%)
Abbreviations: BMI5body mass index, ALT5alanine aminotransferase, AST5 aspartate aminotransferase, GGT5gamma-glutamyl transpeptidase,
HDL5high-density lipoprotein, LDL5low-density lipoprotein, HOMA-IR5homeostasis model of assessment - insulin resistance.
aWe defined persistently high blood pressure as systolic or diastolic blood pressure§95th percentile for age, sex and height or the use of antihypertensive
medication at both baseline and 48 week follow-up. Blood pressure percentiles were computed as instructed in The Fourth Report on the Diagnosis,
Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.
bP values determined from chi square tests for categorical variables and from two-sample Wilcoxon rank sum tests for continuous variables due to the
presence of non-normality.
cAge range from 2–17 years.
dHOMA-IR units are (mg/dL 6 IU/mL/405).
doi:10.1371/journal.pone.0112569.t003
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Unexpectedly, girls with NAFLD had greater odds of persistent high blood
pressure than boys with NAFLD.
The rates of high blood pressure in children with NAFLD exceeded what would
be expected based upon the contribution of obesity alone. Population-based
cohort studies estimate the prevalence of high blood pressure in obese children to
be 11%. [2], [19–21] Although most children with NAFLD are overweight or
obese, our finding that more than one of every three children with NAFLD had
high blood pressure at baseline indicates that children with NAFLD are at
particularly increased risk for high blood pressure. A previous single center study
in overweight and obese children with biopsy-confirmed NAFLD demonstrated
that mean systolic and diastolic blood pressure were significantly higher compared
to overweight and obese controls without evidence of NAFLD. [9] Similarly,
studies in children have shown that hepatic steatosis, independent of degree of
obesity, is associated with cardiac dysfunction. [22], [23] Notably, in our cohort,
children with NAFLD who had high blood pressure at baseline had higher degrees
Table 4. Clinical, Demographic, and Biochemical Risk Factors for Persistently High Blood Pressure.
Odds Ratios (OR) of Persistently High Blood Pressurea
Unadjusted Adjusted, Multivariable Logistic
Characteristic OR (95%CI) P Valueb OR (95% CI) P Valueb
Demographics
Male vs female 0.59 (0.35, 0.99) 0.05 0.49 (0.27, 0.88) 0.02
Age/years 1.00 (0.91, 1.09) 0.98 0.82 (0.73, 0.93) 0.001
Race/ethnicity 0.009 0.12
Non-Hispanic white 1.0 (Reference) 1.0 (Reference)
Hispanic 0.58 (0.34, 0.99) 0.05 0.88 (0.48, 1.61) 0.67
Other 2.08 (0.79, 5.42) 0.14 2.58 (0.90, 7.37) 0.08
Anthropomorphic
BMI/(kg/m2) 1.07 (1.03 1.11) ,0.001 1.10 (1.05, 1.15) ,0.001
Liver enzymes
GGT/(10 U/L) 1.06 (0.99, 1.13) 0.10 1.02 (0.95, 1.11) 0.55
Serum chemistries
LDL/(10 mg/dL) 1.10 (1.01, 1.19) 0.02 1.14 (1.04, 1.24) 0.006
Serum glucose/(10 mg/dL) 1.06 (0.94, 1.19) 0.38 1.07 (0.94, 1.23) 0.31
Serum insulin/(10 mU/mL) 1.03 (0.98, 1.09) 0.26 1.00 (0.94, 1.07) 0.91
Uric acid/(mg/dL) 1.24 (1.04, 1.48) 0.02 1.34 (1.07, 1.67) 0.01
Liver histology
Steatosis grade.33% 1.44 (0.82, 2.55) 0.21 1.82 (0.96, 3.44) 0.07
Intercept 0.003 (0.0002, 0.05) ,0.001
Hosmer-Lemeshow x2 for model fit 0.59
Abbreviations: OR5odds ratio, CI5confidence interval, BMI5body mass index, GGT5gamma-glutamyl transpeptidase, LDL5low-density lipoprotein.
aPersistently high blood pressure was defined as systolic or diastolic blood pressure§95th percentile for age, sex and height or the use of antihypertensive
medication at both baseline and 48 weeks. Blood pressure percentiles were computed as instructed in The Fourth Report on the Diagnosis, Evaluation, and
Treatment of High Blood Pressure in Children and Adolescents.
bP values and 95% CI were obtained from Wald statistics.
doi:10.1371/journal.pone.0112569.t004
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of hepatic steatosis. Data are extremely limited on the persistence of high blood
pressure in children. In our study, the prevalence of 21.4% for persistent high
blood pressure over 48 weeks in children with NAFLD was much higher than
reported for other groups of children with longitudinal data available. For
example, in the National Heart, Lung, and Blood Institute Growth and Health
Study, the rate of persistent high blood pressure over 18 months in girls was 0.6%
overall and 3% in obese girls. [21]
NAFLD and high blood pressure share pathophysiologic factors such as
systemic oxidative stress and vascular and adipose tissue inflammation, which can
produce vascular endothelial dysfunction. [24–28] NAFLD is associated with
endothelial dysfunction independent of obesity and other metabolic syndrome
features. [26] In the setting of hepatic steatosis, liver endothelial dysfunction can
occur even prior to development of hepatic inflammation and fibrosis. [29] While
it is not yet clear whether hypertension is a cause or consequence of endothelial
dysfunction, exogenous infusion of endothelium-derived nitric oxide synthase
inhibitors can produce hypertension in humans. [30] Our finding that elevated
serum levels of LDL-cholesterol and uric acid were associated with increased odds
for both baseline and persistent high blood pressure in this cohort also supports a
possible role for underlying endothelial dysfunction. High levels of LDL
cholesterol have been shown to alter the activity of endothelial-derived nitric
oxide synthase. [31] Oxidized LDL is also associated with endothelial dysfunction
and activation of the renin-angiotensin system. [32], [33] Likewise, elevated uric
acid has been functionally linked to decreased endothelial nitric oxide synthase
activity and nitric oxide production and in turn endothelial dysfunction. [34],
[35] Elevated uric acid levels have been reported in children with NAFLD,
possibly due to high dietary fructose intake. [36] Serum uric acid levels in
childhood have been shown to predict high blood pressure beginning in
childhood and persisting into adulthood. [37], [38] Thus, common pathophy-
siological processes may play a role in the development of both NAFLD and high
blood pressure.
High blood pressure in childhood tracks into adulthood. [4], [5] High blood
pressure in children with NAFLD is, therefore, likely to persist and place these
children at risk for premature morbidity and mortality. Systolic blood pressure in
childhood is a consistent predictor of arterial stiffness in adults. [39] Of the
various metabolic syndrome factors, systolic blood pressure in childhood has the
strongest correlation with coronary artery atherosclerosis in adulthood. [6]
Additionally, adolescents with NAFLD have been shown to have left ventricular
dysfunction compared to obese adolescents without NAFLD. [23] In adults with
NAFLD, high blood pressure is linked to each of the three most common causes of
death; cardiovascular disease, cancer, and liver disease. [40] Furthermore, in
adults with NASH, the presence of hypertension is an important risk factor for the
development of hepatocellular carcinoma. [41] Despite the potential for adverse
outcomes, our data suggest that there is likely an underdiagnosis of high blood
pressure in children with NAFLD. Future studies should assess interventions to
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improve the detection and control of high blood pressure in children with
NAFLD.
The accurate assessment of blood pressure in children with NAFLD was
strengthened by the use of the NASH CRN, the largest prospectively enrolled
cohort of children with NAFLD with representation from across the U.S.
Participants had an accurate diagnosis of NAFLD characterized in a rigorous
standardized fashion. Moreover, the inclusion of longitudinal data is rare and
particularly important for blood pressure research. The study was limited by the
lack of three discrete measures required to confirm a clinical diagnosis of
hypertension. However, large longitudinal cohort studies have shown that a single
measurement of high blood pressure in childhood is strongly associated with
development of hypertension in adulthood. [4] Furthermore, persistent single-
time point measurements of high blood pressure in childhood carry an even
greater risk of subsequent hypertension. [42] Future studies should consider the
use of ambulatory blood pressure monitoring to better define the blood pressure
phenotype in children with NAFLD. [43] Finally, long-term follow-up data are
needed to assess for the development of adverse clinical outcomes associated with
high blood pressure in children with NAFLD.
In conclusion, NAFLD is a common clinical problem that places children at
substantial risk for high blood pressure, which may often go undiagnosed. Thus
blood pressure evaluation and control should be an integral component of the
clinical management of children with NAFLD.
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